Clinical Trials Browser

Phase 1/2 × Carcinoma, Neuroendocrine × durvalumab × Clear all

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma